OptimizeRx (OPRX) said Monday that Chief Executive William J. Febbo will leave the company, effective Dec. 31 and that it appointed Stephen Silvestro as interim CEO.
The digital health technology company said its board hired a search firm to assist in the transition and to help look for a successor. Silvestro was the company's chief commercial officer before becoming president last year, OptimizeRx said.
OptimizeRx said it expects full-year 2024 revenue to come in at the higher end of the $88 million to $92 million guidance range.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。